EUVIMEDEUVIMED entdecken
Crossref

Safety of Prior Propranolol Therapy for Infantile Hemangioma

Iraj Hasan iD, Zachary Zinn

Pediatric Dermatology · 2024-11 · 41 (6) · 1057-1062

DOI: 10.1111/pde.15753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Dermatology, online erschienen am 08.10.2024. Verfasst von Iraj Hasan und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, West Virginia University, Morgantown, West Virginia, USA. Hauptthemen laut MEDLINE: Propranolol, Hemangioma. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Propranolol has been the primary treatment for infantile hemangioma (IH) since 2008. Prior studies have investigated the effects in late childhood of propranolol therapy given in infancy for IH, including neurocognitive dysfunction, sleep disorders, and hypoglycemia. However, few studies have determined the risk of these adverse effects later in life. Using the TrinetX database, we studied the risk of growth impairment, sleep disorders, learning disabilities, and diabetes mellitus in children aged 10–17 years who had received propranolol for IH in infancy. The maximum age of 17 years was chosen for the study, as propranolol was established as a treatment for IH in 2008. The results showed no statistically significant risk of growth impairment, sleep disorders, learning disabilities, or diabetes mellitus in IH patients treated with propranolol. These findings support existing evidence that propranolol therapy given in infancy for IH is not associated with long‐term adverse effects up to age 17 years in the studied patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropranololHemangiomaHumansChildMaleAdolescentFemaleInfantAdrenergic beta-AntagonistsSkin NeoplasmsSleep Wake DisordersLearning DisabilitiesDiabetes Mellitus

Stichwörter der Autor:innen

infantile hemangiomapropranololsafety

Substanzen

PropranololAdrenergic beta-Antagonists

Autor:innen und Institutionen

  • School of Medicine, West Virginia University, Morgantown, West Virginia, USA.
  • Department of Dermatology, West Virginia University, Morgantown, West Virginia, USA.

ORCID-Profile: Iraj Hasan

Zitieren

APA

Hasan, I., & Zinn, Z. (2024). Safety of Prior Propranolol Therapy for Infantile Hemangioma. Pediatric Dermatology, 41(6), 1057-1062. https://doi.org/10.1111/pde.15753

Vancouver

Hasan I, Zinn Z. Safety of Prior Propranolol Therapy for Infantile Hemangioma. Pediatric Dermatology. 2024;41(6):1057-1062. doi:10.1111/pde.15753

BibTeX
@article{Hasan2024,
  author = {Hasan, Iraj and Zinn, Zachary},
  title = {Safety of Prior Propranolol Therapy for Infantile Hemangioma},
  journal = {Pediatric Dermatology},
  year = {2024},
  volume = {41},
  number = {6},
  pages = {1057--1062},
  doi = {10.1111/pde.15753}
}
Kostenlos starten →